CS MEDICA A/S Secures Trademark Approval in Canada
Today, CS MEDICA A/S announces it has secured trademark approval for its brand name CANNASEN® in Canada. A significant milestone for the company’s global footprint and in strengthening its brand recognition globally.
CS MEDICA A/S (“CS MEDICA” or “The Company”), a global MedTech company specializing in CBD and pain management, is proud to take one step closer to the Canadian Market. The company’s mission is to improve patient outcomes globally and enhance the quality of care by providing safe and effective products that alleviate symptoms of autoimmune diseases and stress-related disorders.
The trademark approval covers both 03 Cosmetics, 05 Pharmaceuticals and natural remedies, and 10 Medical devices. This achievement is a testament to the company’s commitment to quality and its ability to meet the highest standards. It also demonstrates the company’s ability to navigate complex regulatory environments and establish a strong brand presence in key markets.
With the approval of its trademark, CS MEDICA A/S is now positioned to further expand its business operations in Canada. The country has a robust healthcare sector that presents significant growth opportunities for the company.
For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
CS MEDICA A/S is a Danish-based MedTech company operating globally within research, development, manufacturing, commercializing, and a part of the pharmaceutical industry. The company combines science and nature with the purpose of creating products for a better every day by using modern technology to research and utilize different compounds found in the cannabis plant. CS MEDICA offers efficient, safe OTC alternative treatments with CBD for autoimmune and stress-related disorders under the trademark CANNASEN® or own-label options.
The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com, and LinkedIn.